In our analysis, a PRS derived from MAX_ALC was associated with AOO of AUD in our high-risk sample. Clinical prediction that includes easily measurable variables, such as comorbid conditions, age of first drink, and peer drinking, shows efficacy (0.88–0.95) that approaches the range of clinical utility (52), with or without PRS. The predictive value of PRS is most evident when the extremes of the PRS distribution are compared, as illustrated by a 1.3-times increase in the probability of developing any AUD and a 2.2-times increase in the probability of developing severe AUD by age 25 among EA individuals from the top and bottom PRS quartiles.
